What do systematic reviews say?

Summary of findings table ‐ Light therapy vs usual care

• Non‐pharmacological interventions for sleep disturbances in people with dementia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 205 participants
  Very low

Summary of findings table ‐ Light therapy vs usual care

• Non‐pharmacological interventions for sleep disturbances in people with dementia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 136 participants
  Very low

Summary of findings table ‐ Light therapy vs usual care

• Non‐pharmacological interventions for sleep disturbances in people with dementia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 3 participants
  Low

Summary of findings table ‐ Light therapy vs usual care

• Non‐pharmacological interventions for sleep disturbances in people with dementia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 318 participants
  Very low

Summary of findings table ‐ Physical activities vs usual care

• Non‐pharmacological interventions for sleep disturbances in people with dementia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 167 participants
  Low

Summary of findings table ‐ Physical activities vs usual care

The review found no eligible studies for this question.

• Non‐pharmacological interventions for sleep disturbances in people with dementia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 612 participants
  Very low

Deferasirox vs deferiprone (DFO)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Deferasirox vs deferiprone (DFO)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 390 participants
  Low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  1.54 [0.44, 5.39]
  1 study · 390 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

It is very uncertain whether summary of findings: Comparison 3 ‐ deferiprone (DFP) changes total SAEs compared with deferasirox (DFX) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.95 [0.46, 1.96]
  1 study · 390 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RD 0
  1 study · 390 participants
  Low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFX film‐coated tablet vs DFX dispersible tablet

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Very low

DFX film‐coated tablet vs DFX dispersible tablet

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes total reported SAEs (from therapy, disease, non‐adherence) compared with deferoxamine (DFO) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 1.43 [0.83, 2.46]
  1 study · 228 participants
  Very low

DFX film‐coated tablet vs DFX dispersible tablet

It is very uncertain whether summary of findings: Comparison 4 ‐ deferasirox (DFX) film‐coated… changes incidence of SAEs compared with DFX dispersible tablets (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 1.22 [0.62, 2.37]
  1 study · 173 participants
  Very low

DFX film‐coated tablet vs DFX dispersible tablet

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  7.3 [0.14, 368.15]
  1 study · 173 participants
  Very low